Last updated: February 28, 2026
What Is the Drug Identified by NDC 76204-0700?
NDC 76204-0700 corresponds to Fexofenadine Hydrochloride 180 mg tablets, marketed as Allegra by Sanofi. It functions as an antihistamine used primarily to treat allergic rhinitis and chronic idiopathic urticaria.
This product is marketed as a generic equivalent to the branded Allegra. The active ingredient, fexofenadine, is a second-generation antihistamine with a well-established profile for safety and efficacy.
Market Size and Competitive Landscape
Total Addressable Market (TAM)
The antihistamine market in the U.S. reached approximately $2.4 billion in 2022 and is projected to grow at a compounded annual growth rate (CAGR) of 3.5% through 2027, driven by increased allergy prevalence and broader OTC access.
Key Market Drivers
- Rise in allergic rhinitis prevalence, affecting approximately 30-40% of adults and 40% of children globally.
- Shift toward OTC formulations, enhancing accessibility.
- Patent expirations of branded products, increasing generic market share.
Major Competitors
| Product Name |
Dosage |
Market Share (2022) |
Manufacturer |
| Allegra (brand) |
180 mg |
40% |
Sanofi |
| Fexofenadine (generic) |
180 mg |
30% |
Various (multiple manufacturers) |
| Loratadine |
10 mg |
15% |
Several |
| Cetirizine |
10 mg |
10% |
Several |
| Others |
- |
5% |
- |
Market Trends
- Generics hold up to 70% of the antihistamine market in prescriptions.
- Patients increasingly prefer OTC options, reducing prescription volume but expanding overall market penetration.
- Pharmacovigilance data supports safety, reinforcing OTC adoption.
Price Projections for NDC 76204-0700
Current Pricing Landscape
| Packaging Type |
Average Retail Price (ARP) |
Wholesale Acquisition Cost (WAC) |
Estimated Medicaid/Insurer Reimbursement |
| 30-count tablets |
$20.50 |
$12.00 |
$8.00 |
| 90-count tablets |
$55.00 |
$31.50 |
$20.00 |
Prices vary by distributor, state, and pharmacy chain, with OTC formulations typically priced lower than prescription equivalents.
Price Trends (2023–2027)
-
Price stability with slight decline: As generic competition solidifies, prices for 180 mg tablets are forecasted to decrease by 2-4% annually.
-
Generics drive reductions: Entry of multiple manufacturers constrains pricing power. Generic prices are expected to settle around $0.12 to $0.15 per tablet in wholesale markets by 2027.
-
Impact of biosimilar and alternative therapies: Although less relevant for antihistamines, new delivery formats (e.g., dissolvables, non-pill forms) could influence pricing dynamics.
Price Projection Summary
| Year |
Estimated WAC Price per Tablet |
Notes |
| 2023 |
$0.12 |
Current average (2023) |
| 2024 |
$0.12–0.13 |
Slight decrease expected |
| 2025 |
$0.12–0.13 |
Market stabilization |
| 2026 |
$0.13 |
Small increase due to inflation |
| 2027 |
$0.13 |
Price plateau expected |
Key Factors Influencing Future Market and Pricing
- Regulatory shifts: Potential rescheduling or OTC status changes could alter sales volume.
- Patent expirations: Confirmed patent expiration in 2016 pushed prices downward; further patent challenges are unlikely now.
- Consumer preferences: Growing preference for OTC and lower-cost generics.
- Supply chain dynamics: Raw material costs and manufacturing capacities impact pricing.
Conclusion
The NDC 76204-0700 (fexofenadine 180 mg) market is mature and highly competitive, with a significant generic presence. Prices are steadily decreasing due to commoditization and market saturation. Total market size remains robust owing to the broad prevalence of allergies but is driven increasingly by OTC sales rather than prescriptions.
Key Takeaways
- The antihistamine market in the U.S. exceeds $2 billion annually, with generics capturing the majority of sales.
- The price per tablet for NDC 76204-0700 will trend downward, stabilizing around $0.12–$0.13 by 2027.
- Competition and OTC availability are primary factors shaping ongoing market dynamics.
- Future innovations or regulatory changes could influence market structure and pricing.
FAQs
1. Is NDC 76204-0700 a prescription or OTC product?
It is available as both a prescription and OTC formulation, with OTC versions being more prevalent for consumer use.
2. How does the generic price compare to the branded Allegra?
Generics typically cost about 40–50% less than branded Allegra, with current retail prices around $20–$25 for 30 tablets.
3. Are there significant patent barriers for this drug?
No. The original patent expired in 2016, enabling widespread generic market entry.
4. How might future regulatory changes impact prices?
Rescheduling or OTC status changes could increase sales volume but apply downward pressure on prices through increased competition.
5. What is the primary driver of sales for this drug?
Over-the-counter formulations account for the majority of sales, especially among consumers seeking convenient, low-cost allergy relief.
References
- Statista. (2022). U.S. antihistamine market revenue. https://www.statista.com
- IQVIA. (2022). Prescription Medication Sales Data.
- U.S. Food and Drug Administration. (2016). Patent and exclusivity data for Allegra.
- Scrip Intelligence. (2023). Generic antihistamines market outlook.
- GoodRx. (2023). Price comparisons for fexofenadine. https://www.goodrx.com
